Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
The precise diagnosis of HCC is confronted with severe challenges due to the tumor heterogeneity and insidious symptoms of hepatocellular carcinoma (HCC), and meanwhile the limitations of positron emission tomography (PET) with traditional 2-deoxy-2-[fluorine-18] fluoro-d-glucose (F-FDG) tracer. Given that angiotensin II type 1 receptor (AT1R) is significantly upregulated in HCC and closely related to its progression, we have developed a novel Ga-radiolabeled compound, Ga-DOTA-AngII (Ga-DOTA-GGDRVYIHPF), and evaluated its HCC detection capability. Ga-DOTA-AngII demonstrated acceptable stability in both human plasma and phosphate buffered saline. In vivo imaging and in vitro biodistribution analysis in tumor-bearing mice showed that Ga-DOTA-AngII demonstrate a high tumor uptake, and the tumor tissue exhibited rapid uptake. In brief, this radiotracer possesses a promising potency for imaging the expression of AT1R for further clinical application.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.bmc.2025.118221 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Abbreviated liver magnetic resonance imaging with a second-shot arterial phase image to assess the viability of treated hepatocellular carcinoma after non-radiation locoregional therapy.
Diagn Interv Radiol
September 2025
Department of Internal Medicine, Biomedical Research Institute, Pusan National University Hospital, Pusan National University School of Medicine, Busan, Korea.
Purpose: To evaluate the feasibility of abbreviated liver magnetic resonance imaging (AMRI) with a second-shot arterial phase (SSAP) image for the viability of treated hepatocellular carcinoma (HCC) after non-radiation locoregional therapy (LRT).
Methods: We retrospectively enrolled patients with non-radiation LRT for HCC who underwent the modified gadoxetic acid-enhanced liver MRI protocol, which includes routine dynamic and SSAP imaging after the first and second injection of gadoxetic acid, respectively (6 mL and 4 mL, respectively), and an available reference standard for tumor viability in the treated HCC between March 2021 and February 2022. Two radiologists independently reviewed the full-protocol MRI (FP-MRI) and AMRI with SSAP.
MRI-based radiomics signatures for predicting the efficacy of targeted therapy with lenvatinib in hepatocellular carcinoma: a retrospective cohort study.
J Cancer Res Clin Oncol
September 2025
Department of Radiology, Guizhou Provincial People's Hospital, No. 83 East Zhongshan Road, Guiyang, 550002, Guizhou, China.
Purpose: Targeted therapy with lenvatinib is a preferred option for advanced hepatocellular carcinoma, however, predicting its efficacy remains challenging. This study aimed to build a nomogram integrating clinicoradiological indicators and radiomics features to predict the response to lenvatinib in patients with hepatocellular carcinoma.
Methods: This study included 211 patients with hepatocellular carcinoma from two centers, who were allocated into the training (107 patients), internal test (46 patients) and external test set(58 patients).
Agranulocytosis Following Durvalumab Plus Tremelimumab Therapy for Hepatocellular Carcinoma: A Case Report.
Intern Med
September 2025
Department of Gastroenterology and Hepatology, Toyota Kosei Hospital, Japan.
Agranulocytosis is an extremely rare but potentially fatal immune-related adverse event (irAE) induced by immune checkpoint inhibitors (ICIs). Its management, particularly following combination therapies such as durvalumab/tremelimumab (Dur/Tre) for hepatocellular carcinoma (HCC), is challenging owing to limited data. We herein report a 79-year-old man with HCC who developed severe Dur/Tre-induced agranulocytosis that was refractory to granulocyte colony-stimulating factor, high-dose corticosteroids, and intravenous immunoglobulin.
View Article and Find Full Text PDF[Liver transplantation for hepatocellular carcinoma].
Nihon Shokakibyo Gakkai Zasshi
January 2025
Department of Surgery, Graduate School of Medicine, Kyoto University.
Disease-associated hepatocytes are predictive of outcomes and survival in MASLD beyond fibrosis staging.
Gut
September 2025
Curtin Medical School, Curtin University, Bentley, Western Australia, Australia